Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead Candidate

• Cassava Sciences Inc (NASDAQ: SAVA) has entered into a definitive agreement with several institutional investors for the purchase of 4.1 million common shares at per share, for gross proceeds of approximately $200 million, in a registered direct offering. The offer price is at a 15% discount from the last close price of $57.56 on Tuesday.

• H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering and is expected to close by February 12.

• Cassava Sciences intends to use the net proceeds to develop simufilam, its lead drug candidate for Alzheimer's disease.

• Earlier this week, shares rallied after the company announced expanding the size of the ongoing simufilam open-label study and its plans to initiate a six-month study in patients who complete at least one year of open-label treatment with simufilam.

• Price Action: SAVA dropped 12.7% at $50.27 during premarket trading hours on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• BioNTech Starts Production At New Germany Plant In Boost For COVID-19 Shots

• Autolus Therapeutics Raises 0M Via Equity

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.